Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 12/20 | 0.36 |
| ▸ | NR1H4 | Q96RI1 | 5/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27213933 | 1.00 | P2RX7 (0.36) | P2RX7NR1H4HDAC4HDAC6CNR2 | |
| SCHEMBL29318668 | 1.00 | P2RX7 (0.36) | P2RX7NR1H4HDAC4HDAC6CNR2 | |
| SCHEMBL30893012 | 0.88 | NR1H4 (0.34) | P2RX7NR1H4HDAC4HDAC6CNR2 | |
| SCHEMBL27213811 | 0.88 | NR1H4 (0.34) | P2RX7NR1H4HDAC4HDAC6CNR2 | |
| SCHEMBL27395063 | 0.88 | NR1H4 (0.34) | P2RX7NR1H4HDAC4HDAC6CNR2 | |
| SCHEMBL30892933 | 0.88 | P2RX7 (0.33) | P2RX7NR1H4 | |
| SCHEMBL29318672 | 0.88 | P2RX7 (0.33) | P2RX7NR1H4 | |
| SCHEMBL27213922 | 0.88 | P2RX7 (0.33) | P2RX7NR1H4 | |
| SCHEMBL29318671 | 0.87 | NR1H4 (0.35) | P2RX7NR1H4HDAC4HDAC6CNR2 | |
| SCHEMBL30892999 | 0.87 | NR1H4 (0.35) | P2RX7NR1H4HDAC4HDAC6CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238425-A1 | HSD17B13 Inhibitors and/or Degraders | PFIZER INC. (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240150334-A1 | HSD17B13 INHIBITORS AND/OR DEGRADERS | PFIZER INC. (US) | 2024-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238425-A1 | HSD17B13 Inhibitors and/or Degraders | HSD17B13, HSD17B3, HSD17B1 | P2RX7 4636/4885NR1H4 94/4885HDAC4 450/4885 |
| US-20240150334-A1 | HSD17B13 INHIBITORS AND/OR DEGRADERS | HSD17B1, HSD17B3, HSD17B13 | P2RX7 4666/4885NR1H4 94/4885HDAC4 513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.